Deep learning for wireless capsule endoscopy: a systematic review and meta-analysis - 21/09/20
Abstract |
Background and Aims |
Deep learning is an innovative algorithm based on neural networks. Wireless capsule endoscopy (WCE) is considered the criterion standard for detecting small-bowel diseases. Manual examination of WCE is time-consuming and can benefit from automatic detection using artificial intelligence (AI). We aimed to perform a systematic review of the current literature pertaining to deep learning implementation in WCE.
Methods |
We conducted a search in PubMed for all original publications on the subject of deep learning applications in WCE published between January 1, 2016 and December 15, 2019. Evaluation of the risk of bias was performed using tailored Quality Assessment of Diagnostic Accuracy Studies-2. Pooled sensitivity and specificity were calculated. Summary receiver operating characteristic curves were plotted.
Results |
Of the 45 studies retrieved, 19 studies were included. All studies were retrospective. Deep learning applications for WCE included detection of ulcers, polyps, celiac disease, bleeding, and hookworm. Detection accuracy was above 90% for most studies and diseases. Pooled sensitivity and specificity for ulcer detection were .95 (95% confidence interval [CI], .89-.98) and .94 (95% CI, .90-.96), respectively. Pooled sensitivity and specificity for bleeding or bleeding source were .98 (95% CI, .96-.99) and .99 (95% CI, .97-.99), respectively.
Conclusions |
Deep learning has achieved excellent performance for the detection of a range of diseases in WCE. Notwithstanding, current research is based on retrospective studies with a high risk of bias. Thus, future prospective, multicenter studies are necessary for this technology to be implemented in the clinical use of WCE.
Le texte complet de cet article est disponible en PDF.Abbreviations : AI, CCE, CCC, WCE
Plan
| DISCLOSURE: The following authors disclosed financial relationships: R. Eliakim: Speaker for Takeda, Jansen, and Medtronic. S. Ben-Horin: Consultant and advisory board for and research support from AbbVie, MSD, Jansen, Takeda, Pfizer, GSK, and CellTrion. U. Kopylov: Research support from Jannsen, Takeda, and Medtronic; advisory fees from Jannsen, Takeda, Medtronic, Abbvie, Dr Falk, and MSD. All other authors disclosed no financial relationships. |
|
| See CME section, p. 960. |
|
| If you would like to chat with an author of this article, you may contact Dr Soffer at soffer.shelly@gmail.com. |
Vol 92 - N° 4
P. 831 - octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
